Straggle to Publish? Medicare Drug Idea Lawsuit Quashed; Inform Curbs Most cancers Anxiety

The composed retraction of a journal article on abdominal cancer with “suspicious records” has shone a gentle-weight on publishers’ desire “to position out enormous volumes of experiences while avoiding the reputational injury of retracting them publicly.” (Fresh York Cases)

The FDA is in the aid of agenda on providing steering to drug and plot makers about the final note technique to elevate patient vary in clinical trials. (Regulatory Point of interest)

A bipartisan community of senators despatched FDA Commissioner Robert Califf, MD, a letter encouraging motion to curb misleading adverts promoting advantages of medication on social media. (Wall Avenue Journal)

Pretreatment with a histone deacetylase inhibitor led to encouraging response charges with immunotherapy for developed HER2-harmful breast cancer, significantly triple-harmful breast cancer (TNBC). (Johns Hopkins Medication, Nature Most cancers)

Review of cancer genetics with multigene panels elevated healthcare charges and not utilizing a most indispensable improvement in total survival. (ESMO, eClinicalMedicine)

A Belgian boy has turn into the most indispensable shrimp one identified to be cured of an aggressive fabricate of mind cancer identified as brainstem glioma. (Science Alert)

A federal judge pushed apart a lawsuit by Pharmaceutical Research and Producers of The usa no longer easy the Biden administration’s plot to enable Medicare to negotiate drug prices. (Reuters)

Neoadjuvant immunotherapy for tender-tissue sarcomas led to an encouraging 2-yr survival of 82-90%. (University of Texas MD Anderson Most cancers Center, Nature Most cancers)

Bodily inform change into once associated to greatly less patient-reported cancer danger. (Most cancers)

G1 Therapeutics announced termination of a allotment III trial of trilaciclib (Cosela) in developed colon cancer thanks to lack of efficacy nevertheless will continue a allotment III trial of the drug in metastatic TNBC. (Reuters)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and likewise covers urology, dermatology, and ophthalmology. He joined MedPage This present day in 2007. Note

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button